More Reforms Needed To Raise China Healthcare Quality: AmCham
This article was originally published in PharmAsia News
Executive Summary
The China FDA needs to do more to reduce a piling up drug approval backlog, while other issues such as clinical trial reviews, incentives for R&D and pricing in China are all of concern to the pharma industry, the American Chamber of Commerce says in its latest white paper.